

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 9/10 (2006.01)(21) International Application Number:
PCT/EP2021/058112(22) International Filing Date:
29 March 2021 (29.03.2021)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
63/002,287 30 March 2020 (30.03.2020) US(71) Applicant: **BIONTECH SE** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).(72) Inventors: **SAHIN, Ugur**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **LINDEMANN, Claudia**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **DIEKMANN, Jan**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **BRET-TSCHNEIDER, Kerstin**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **BÄHR-MAHMUD, Hayat**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **ELLINGHAUS, Ursula**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **FISCHER, Leyla**; c/o BioNTech RNA Pharmaceu-ticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **STADLER, Christiane**; c/o BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131 Mainz (DE). **TÜRECI, Özlem**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: RNA COMPOSITIONS TARGETING CLAUDIN-18.2



(57) Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g., but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g., in combination with a chemotherapeutic agent).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*